Two Sigma Advisers’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Two Sigma Advisers’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,500	Closed	-$454K	–	2728
2023 Q1	$454K	Sell	2,500 -88,900	-97%	-$17M	﹤0.01%	1978
2022 Q4	$18M	Buy	91,400 +16,700	+22%	+$3.58M	0.05%	371
2022 Q3	$16.8M	Buy	+74,700	New	+$15.1M	0.05%	364
2022 Q2	–	Sell	-2,300	Closed	-$292K	–	2942
2022 Q1	$292K	Buy	2,300 +400	+21%	+$45K	﹤0.01%	2230
2021 Q4	$249K	Sell	1,900 -800	-30%	-$103K	﹤0.01%	2206
2021 Q3	$330K	Buy	2,700 +100	+4%	+$11.5K	﹤0.01%	2079
2021 Q2	$296K	Sell	2,600 -700	-21%	-$81.8K	﹤0.01%	2146
2021 Q1	$397K	Sell	3,300 -2,500	-43%	-$283K	﹤0.01%	2110
2020 Q4	$589K	Buy	+5,800	New	+$537K	﹤0.01%	1808
2020 Q1	–	Sell	-3,500	Closed	-$264K	–	2600
2019 Q4	$264K	Buy	+3,500	New	+$153K	﹤0.01%	2103

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's KRTX Position: Q2 2023 in Review

Two Sigma Advisers sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 2,500 shares — an estimated $454K sold.

Two Sigma Advisers first reported a position in KRTX in Q4 2019 and held it in 10 quarters. The position peaked at $18M in Q4 2022. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

Two Sigma Advisers reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Two Sigma Advisers sold 2,500 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $454K.
Two Sigma Advisers first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 10 quarters.
Two Sigma Advisers's Karuna Therapeutics, Inc. Common Stock position peaked at $18M in Q4 2022.
289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.